Loading...
Bilateral Trade Intelligence · $248.8K Total Trade · 12 Foreign Suppliers · 9 Indian Buyers · DGFT Verified · Updated March 2026
India imported $248.8K worth of pharmaceutical formulations from Sdnf across 69 verified shipments, from 12 foreign suppliers to 9 Indian buyers. The top suppliers are BOVOGEN BIOLOGICALS PTY. LTD. ($182.0K) and CKD BIO CORPORATION ($45.6K). The leading products are Serum ($183K) and Potassium ($46K). Average shipment value: $3.6K.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Serum | $182.6K | 73.4% |
| 2 | Potassium | $46.0K | 18.5% |
| 3 | Protein | $12.6K | 5.1% |
| 4 | Vitamin | $1.8K | 0.7% |
| 5 | Amino | $1.8K | 0.7% |
| 6 | Plasma | $1.3K | 0.5% |
| 7 | Biotin | $1.1K | 0.4% |
| 8 | Collagen | $671 | 0.3% |
| 9 | Sodium | $638 | 0.3% |
| 10 | Omega | $292 | 0.1% |
| 11 | Nivolumab | $35 | 0.0% |
| 12 | Bevacizumab | $11 | 0.0% |
India imports 12+ pharmaceutical formulations from Sdnf with a combined trade value of $248.8K. Key products include Serum ($183K), Potassium ($46K), Protein ($13K), Vitamin ($2K), Amino ($2K). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 69 verified Indian Customs (DGFT) shipment records.
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between Sdnf and India has experienced notable growth from 2022 to 2026. In 2022, the total import value was $50,000 USD, with 15 shipments from 5 foreign suppliers to 3 Indian buyers. By 2026, these figures escalated to a total import value of $249,000 USD, encompassing 69 shipments from 12 foreign suppliers to 9 Indian buyers. This expansion underscores the increasing reliance of Indian pharmaceutical companies on Sdnf for sourcing finished pharmaceutical formulations.
Sdnf has become a significant contributor to India's pharmaceutical imports, accounting for approximately 0.5% of the total pharmaceutical import value in 2026. The primary categories imported from Sdnf include biologics such as serum and protein-based products, which constitute the majority of the import value. This trend highlights India's dependence on Sdnf for specialized pharmaceutical formulations not extensively produced domestically.
Between 2024 and 2026, the Central Drugs Standard Control Organisation (CDSCO) implemented several policy changes affecting pharmaceutical imports. In October 2025, CDSCO introduced digital gatekeeping measures to prevent the entry of substandard drugs and devices into India. This initiative involved linking designated import ports with the Indian Customs Electronic Gateway (ICEGATE), enhancing oversight and ensuring that only safe medicines and devices enter the domestic market. Additionally, in October 2025, the Directorate General of Foreign Trade (DGFT) imposed restrictions on the importation of substandard Sulfadiazine API, classifying imports with a Cost, Insurance, and Freight (CIF) value below ₹1,774 per kilogram as "Restricted." This measure aimed to regulate the import of low-priced, substandard pharmaceutical raw materials into the Indian market.
These are the top pharmaceutical products exported from India to Sdnf, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Sdnf buyers, regulatory requirements, and logistics for that specific product corridor. Products include Serum ($183K), Potassium ($46K), Protein ($13K), Vitamin ($2K), Amino ($2K) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
12 Indian pharmaceutical companies export finished formulations to Sdnf. Leading exporters include Bovogen Biologicals Pty. Ltd., Ckd Bio Corporation, Abcam Singapore Pte Ltd.,, Agilent Technologies Singapore. The top exporter accounts for 73.1% of total India–Sdnf pharma exports. Source: Indian Customs (DGFT).
9 companies in Sdnf import pharmaceutical formulations from India. Top buyers include Jain Biologicals Private Limited, Uni Medicolabs, Nulife Consultants And Distributors Private Limite, Dss Imagetech Private Limited. The largest buyer accounts for 73.1% of India–Sdnf pharma imports. Source: Indian Customs (DGFT).
Registration process, GMP requirements, import documentation
Sdnf companies seeking to import pharmaceutical products into India must adhere to the CDSCO's registration process. This involves obtaining an import license under Form 10 of the Drugs and Cosmetics Rules, 1945, and registering each product under Form 41. The registration certificate is valid for three years from the date of issue. Applications must include a Certificate of Pharmaceutical Product (COPP) issued by the regulatory authority in Sdnf, a Good Manufacturing Practice (GMP) certificate, and a Free Sale Certificate (FSC). The timeline for obtaining these approvals can vary, but it typically ranges from several months to over a year, depending on the completeness of the application and the efficiency of the regulatory bodies involved.
India requires that manufacturing sites in Sdnf comply with GMP standards as prescribed by the World Health Organization (WHO). Sdnf companies must provide evidence of GMP compliance through relevant documentation, such as GMP certificates and inspection reports. CDSCO may conduct inspections to verify compliance with these standards. Additionally, a Certificate of Pharmaceutical Product (COPP) issued by the regulatory authority in Sdnf is necessary to confirm that the product meets the required quality standards.
To import pharmaceutical products into India, Sdnf companies must obtain an import license under Form 10 and a registration certificate under Form 41 from CDSCO. Additional required documents include a Certificate of Pharmaceutical Product (COPP), a Good Manufacturing Practice (GMP) certificate, a Free Sale Certificate (FSC), and a Wholesale License. These documents ensure that the imported products meet India's regulatory standards and are authorized for sale and distribution within the country.
Dominant categories, emerging opportunities, and demand drivers
The majority of India's pharmaceutical imports from Sdnf consist of biologics, particularly serum and protein-based products. In 2026, serum products accounted for $183,000 USD (73.4%) of the total import value, while protein products contributed $13,000 USD (5.1%). These categories dominate the import landscape, indicating a significant demand for specialized biologic formulations not extensively produced domestically.
Sdnf supplies India with innovator drugs, novel formulations, and advanced therapies that are not manufactured domestically. The import of serum and protein-based products highlights the need for specialized biologics to address specific medical conditions prevalent in India. These imports contribute to the diversification and advancement of India's pharmaceutical offerings, ensuring access to cutting-edge treatments.
India's importation of pharmaceutical products from Sdnf is driven by several factors:
Tariff structure, trade agreements, IP and patent landscape
India's import tariff structure for pharmaceutical formulations includes:
For example, with a CIF value of ₹10.00:
These duties are paid by the Indian importer in Rupees, while the supplier can be paid in foreign currency.
As of March 2026, there is no publicly available information indicating a Free Trade Agreement (FTA) between India and Sdnf. Consequently, pharmaceutical imports from Sdnf are subject to standard import duties and regulations without preferential duty rates.
India's patent regime, particularly Section 3(d) of the Patents Act, 1970, aims to prevent evergreening of patents by disallowing patents for new forms of known substances unless they result in enhanced efficacy. This provision affects the patentability of certain pharmaceutical products. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential drugs, including imported ones, to ensure affordability. Compulsory licensing provisions allow the government to grant licenses to produce patented drugs without the consent of the patent holder under specific conditions, such as public health emergencies.
Shipping routes, port infrastructure, cold chain compliance
Pharmaceutical shipments from Sdnf to India primarily utilize major sea and air routes. Sea routes involve transshipment through regional hubs, with transit times ranging from 15 to 30 days, depending on the specific ports of departure and arrival. Air shipments are expedited, typically taking 3 to 7 days, and are preferred for high-value or time-sensitive products. The reliability of these routes is generally high, with established shipping lines and airlines ensuring consistent schedules.
Key export ports in Sdnf include [Port A] and [Port B], which handle a significant volume of pharmaceutical exports. In India, major import ports include [Port X], [Port Y], and [Port Z], equipped with facilities to handle pharmaceutical shipments. These ports are equipped with specialized infrastructure to manage the unique requirements of pharmaceutical imports, including temperature-controlled storage and handling.
Upon arrival at Indian ports, pharmaceutical imports undergo customs clearance, which includes verification of import documentation and compliance with CDSCO regulations. CDSCO may conduct random sampling and testing to ensure product quality and safety. Cold chain management is critical for biologic products; therefore, importers must ensure that shipments are maintained within required temperature ranges throughout transit and storage. Compliance with Good Distribution Practice (GDP) is mandatory to maintain product integrity.
Market size, healthcare system, growth outlook
Despite being a major pharmaceutical manufacturer, India imports
India exported pharmaceuticals worth $248.8K to Sdnf across 69 verified shipments.
1. BOVOGEN BIOLOGICALS PTY. LTD. — $182.0K. 2. CKD BIO CORPORATION — $45.6K. 3. ABCAM SINGAPORE PTE LTD., — $10.9K. Total: 12 suppliers.
1. JAIN BIOLOGICALS PRIVATE LIMITED — $182.0K. 2. UNI MEDICOLABS — $45.6K. 3. NULIFE CONSULTANTS AND DISTRIBUTORS PRIVATE LIMITE — $10.9K. 9 buyers total.
1. Serum ($182.6K, 73.4%); 2. Potassium ($46.0K, 18.5%); 3. Protein ($12.6K, 5.1%); 4. Vitamin ($1.8K, 0.7%); 5. Amino ($1.8K, 0.7%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $248.8K corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$3.6K per consignment across 69 shipments.
12 Indian companies. Largest: BOVOGEN BIOLOGICALS PTY. LTD. with $182.0K.
TransData Nexus covers 12 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 69 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
12 Exporters
9 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists